Ma Kuang Healthcare Holding Limited (TPEX:4139)
37.70
0.00 (0.00%)
Aug 18, 2026, 1:30 PM CST
TPEX:4139 Revenue
Ma Kuang Healthcare Holding had revenue of 254.10M TWD in the quarter ending March 31, 2026, a decrease of -3.62%. This brings the company's revenue in the last twelve months to 1.08B, down -4.45% year-over-year. In the year 2025, Ma Kuang Healthcare Holding had annual revenue of 1.09B, down -3.34%.
Revenue (ttm)
1.08B
Revenue Growth
-4.45%
P/S Ratio
1.57
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.70B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.09B | -37.75M | -3.34% |
| Dec 31, 2024 | 1.13B | -87.85M | -7.21% |
| Dec 31, 2023 | 1.22B | 159.37M | 15.05% |
| Dec 31, 2022 | 1.06B | 99.29M | 10.35% |
| Dec 31, 2021 | 959.45M | 49.21M | 5.41% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| PharmaEssentia | 20.75B |
| Synbio Tech | 1.01B |
| AViTA | 972.61M |
| Medical Imaging | 915.34M |
| Taiwan Biomaterial | 182.32M |
| Caliway Biopharmaceuticals | 29.39M |
| Pell Bio-Med Technology | 28.93M |
| Anti-Microbial Savior BioteQ | 706.00K |